Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update

$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $IPHA alert in real time by email

Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. In addition, the Company will hold a conference call on Thursday, September 14, 2023, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2023.

  • Citi's 18th Annual BioPharma Conference

    Event Date: September 6 – 7, Boston
  • H.C. Wainwright 25th Annual Global Investment Conference

    Event Date: September 11 – 13, New-York
  • Morgan Stanley 21st Annual Global Healthcare Conference

    Event Date: September 11 – 13, New-York
  • First Half 2023 Financial Results and Business Update

    Event Date: September 14 – Conference call and Webcast

 

Details for the First Half 2023 Business Update Virtual Event

 

Thursday, September 14, 2023, at 2 p.m. CEST / 8 a.m. EDT

 

The live webcast will be available at the following link:

https://events.q4inc.com/attendee/859850812

 

Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4E60903

 

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

 

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate's portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Get the next $IPHA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IPHA

DatePrice TargetRatingAnalyst
9/17/2021$7.00 → $9.00Outperform
SVB Leerink
9/3/2021$7.00Mkt Perform → Outperform
SVB Leerink
9/3/2021Market Perform → Outperform
SVB Leerink
9/2/2021Market Perform → Outperform
SVB Leerink
More analyst ratings

$IPHA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

    Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") will host an event for institutional investors and analysts dedicated to its Antibody-Drug Conjugate (ADC) strategy, and particularly Nectin-4, the target of its lead antibody-drug candidate program, IPH4502. The event will be held in New York in a hybrid format on Wednesday, February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT. "As we just updated our strategy with a focus on our ANKET® platform and ADC programs, this meeting will be an opportunity to share the latest scientific and clinic

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

    Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as of December 31, 2024: Total number of shares outstanding: 83,830,336 ordinary shares   6,494 Preferred Shares 2016 7,581 Preferred Shares 2017     Total number of theoretical voting rights (1): 84,585,576 Total number of exercisable voting rights (

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Innate Pharma Announces Transformative Strategy to Accelerate Growth

     Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET® NK-cell engager Platform Accelerate development of differentiated Antibody-Drug Conjugates Advance current late-stage assets through partnerships Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. "Our updated strategy underscores Innate Pharma's unwavering dedication

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IPHA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IPHA
SEC Filings

See more

$IPHA
Leadership Updates

Live Leadership Updates

See more
  • Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

    Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO and co-founder Hervé Brailly will support the transition Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vice President and General Manager, Europe

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

    Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and is appointed Executive Vice President, President of US Operations and to the Executive Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that it has strengthened the Company's leadership and corporate governance with the appointment of two new Executive Board members. Arvind Sood, Executive Vice President (EVP), President of US Operations, Dr Sonia Quaratino, EVP, Ch

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Outcome of Innate Pharma's 2022 Annual General Meeting

    Appointment of Dr Sally Bennett to the Supervisory Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took place on May 20, 2022, in Marseille. All resolutions were voted on in accordance with the Executive Board's recommendations. A total of 134 votes were cast out of a total of 32,598,725 shares giving right to 33,088,040 voting rights, representing a quorum of 40.88%. The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2022 section of the Compan

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IPHA
Financials

Live finance-specific insights

See more
  • Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

    Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors Preclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITC Cash position of €96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

    Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2024. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Arvind Sood, Executive Vice President, President of US Operations Details for the Virtual Event The live webcast will be availa

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Innate Pharma Reports First Half 2024 Business Update and Financial Results

    Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH61011 first-in-human study advanced to Phase 2 and initiation of front-line AML Phase 1/2 combination study Updated data from dose-escalation part presented at EHA 2024 confirm clinical benefit and durable responses in patients with R/R AML IPH45, proprietary anti Nectin-4 ADC progressing towards Phase 1 in H2 2024 Monalizumab data from AstraZeneca-sponsored Phase 2 study in early NSCLC presented at WCLC Cash position of €102.1 million2 as of June 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CEST

    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IPHA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more